Ironwood Pharmaceuticals (IRWD) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UPDATE: Credit Suisse Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral
November 7, 2018 5:15 AM EST(Updated - November 7, 2018 7:56 AM EST)
(updated to add analyst comments)
Credit Suisse analyst Vamil Divan downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Outperform to Neutral with a price target of $14.00 (from $22.00) citing disappointing updates on key product Linzess and what... More
JPMorgan Downgrades Ironwood Pharmaceuticals (IRWD) to Underweight
November 7, 2018 5:10 AM ESTJPMorgan analyst Eric Joseph downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Underweight with a price target of $11.00 (from $20.00).
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $12.78 yesterday.
... More